| Literature DB >> 28594170 |
Domenico Schillaci1, Virginia Spanò1, Barbara Parrino1, Anna Carbone1, Alessandra Montalbano1, Paola Barraja1, Patrizia Diana1, Girolamo Cirrincione1, Stella Cascioferro1.
Abstract
There is urgent need for new therapeutic strategies to fight the global threat of antibiotic resistance. The focus of this Perspective is on chemical agents that target the most common mechanisms of antibiotic resistance such as enzymatic inactivation of antibiotics, changes in cell permeability, and induction/activation of efflux pumps. Here we assess the current landscape and challenges in the treatment of antibiotic resistance mechanisms at both bacterial cell and community levels. We also discuss the potential clinical application of chemical inhibitors of antibiotic resistance mechanisms as add-on treatments for serious drug-resistant infections. Enzymatic inhibitors, such as the derivatives of the β-lactamase inhibitor avibactam, are closer to the clinic than other molecules. For example, MK-7655, in combination with imipenem, is in clinical development for the treatment of infections caused by carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa, which are difficult to treat. In addition, other molecules targeting multidrug-resistance mechanisms, such as efflux pumps, are under development and hold promise for the treatment of multidrug resistant infections.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28594170 DOI: 10.1021/acs.jmedchem.7b00215
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446